Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It concentrates on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Oramed Pharmaceuticals will transfer its proprietary POD™ oral drug delivery technology to Lifeward in exchange for a 49.9% ownership stake in the medical robotics company. - The transaction includes up to $47 million in strategic investment designed to bring Lifeward to profitability while expanding into biotechnology through the oral insulin platform. - Lifeward's existing FDA-approved ReWalk® and AlterG® products generated $26 million in revenue over the last four quarters, providing a foundation for the combined entity. - The POD™ technology targets the $600+ billion injectable drugs market, with lead candidate ORMD-0801 having potential to become the world's first commercialized oral insulin medicine.
- Oramed Pharmaceuticals is launching a 60-patient U.S. trial for its oral insulin program after identifying high-responder subgroups showing potential for over 1% HbA1c reduction. - The company terminated its joint venture with Hefei Tianhui Biotech and will continue oral insulin development independently to maintain full control. - Oramed's diversified investment portfolio has grown total assets to approximately $210 million by September 2025, up from $155.7 million in January 2023. - The company maintains its commitment to shareholder rewards including plans for a one-time dividend despite continuing the oral insulin program independently.
- Oramed Pharmaceuticals has invested $36.9 million in Alpha Tau Medical, acquiring approximately 14.1 million shares and establishing a three-year strategic collaboration to accelerate Alpha DaRT cancer therapy development. - The partnership unites two therapeutic delivery innovators—Oramed's oral drug delivery platform with Alpha Tau's precision alpha-radiation technology—with Oramed providing capital markets expertise and appointing two directors to Alpha Tau's board. - Alpha Tau is currently expanding clinical trials across four U.S. indications, developing applications for internal organs, and scaling manufacturing capacity for its breakthrough solid tumor treatment technology.
- Oramed Pharmaceuticals is set to initiate a Phase 3 trial of its oral insulin capsule, ORMD-0801, focusing on patient subpopulations that showed positive responses in prior studies. - The trial protocol is differentiated and aligned with positive subpopulation data, informed by discussions with the FDA, and will be conducted in the U.S. - Oramed has strengthened its financial position through strategic agreements, including a joint venture with Hefei Tianhui Biotech and refinancing initiatives, ensuring sufficient capital for ongoing R&D. - Beyond diabetes, Oramed is exploring the potential of ORMD-0801 for treating nonalcoholic steatohepatitis (NASH) and obesity, expanding its therapeutic applications.
